13 completed, 4 terminated, 3 active not recruiting, 3 not yet recruiting. 29 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 29 | Completed 13, Terminated 4, Active not recruiting 3, Not yet recruiting 3, Unknown 3, Recruiting 2, Withdrawn 1 |
| Phase 2 | 2 | Not yet recruiting 1, Unknown 1 |
Follow Arteritis: new trials by email Literature Review of Arteritis trials Research Report on Arteritis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis Acetyl Salicylic Acid (ASA), Placebo - Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS) | Phase 3 | Not yet recruiting | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | 120 | 2027-10-01 | 2026-10-30 |
| Reducing Arterial Inflammation Using Eplerenone and Statins in HIV Eplerenone, Placebo - HIV (Human Immunodeficiency Virus), Cardiovascular Diseases (CVD) | Phase 2 / Phase 3 | Not yet recruiting | Massachusetts General Hospital | 124 | 2027-03-01 | 2026-10-23 |
| Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone Prednisone - Giant Cell Arteritis (GCA) | Phase 3 | Not yet recruiting | Insel Gruppe AG, University Hospital Bern | 178 | 2026-07-01 | 2026-05-01 |
| TocilizuMab discontinuAtion in GIant Cell Arteritis Tocilizumab treatment, questionnaires, Blood samples - Giant Cell Arteritis | Phase 3 | Active not recruiting | Centre Hospitalier Universitaire Dijon | 120 | 2024-05-13 | 2026-05-04 |
| Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis Tofacitinib 5 MG, Prednisolone, Placebo of tofacitinib 5mg - Takayasu Arteritis | Phase 3 | Unknown | Chinese SLE Treatment And Research Group | 50 | 2023-01-20 | 2023-03-01 |
| Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Secukinumab 300 mg, s.c., Placebo to match Secukinumab, s.c. - Giant Cell Arteritis | Phase 3 | Completed | Novartis Pharmaceuticals | 151 | 2022-09-29 | 2026-02-27 |
| Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) Secukinumab 300 mg, Placebo, Secukinumab 150 mg - Giant Cell Arteritis (GCA) | Phase 3 | Completed | Novartis Pharmaceuticals | 354 | 2021-10-06 | 2026-03-31 |
| Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement Tocilizumab, Placebo - Giant Cell Arteritis, Neurovascular Disorder | Phase 3 | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 66 | 2021-09-24 | 2025-06-25 |
| A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Ustekinumab, Placebo, Glucorticoid Taper Regimen - Takayasu Arteritis | Phase 3 | Terminated | Janssen Pharmaceutical K.K. | 14 | 2021-09-15 | 2025-04-29 |
| Abatacept for the Treatment of Giant Cell Arteritis Abatacept, Placebo - Giant Cell Arteritis | Phase 3 | Recruiting | University of Pennsylvania | 78 | 2021-03-29 | 2026-08-20 |
| Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering Corticosteroids for Systemic Use - Giant Cell Arteritis | Phase 3 | Recruiting | University Hospital, Caen | 150 | 2021-03-03 | 2026-06-26 |
| A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) Upadacitinib, Placebo for Upadacitinib, Prednisolone - Takayasu Arteritis (TAK) | Phase 3 | Active not recruiting | AbbVie | 56 | 2020-02-04 | 2026-02-18 |
| Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO treatment - Arteritis, Giant Cell, Blindness and Low Vision | Phase 3 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2020-02-04 | 2026-06-18 |
| MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial Prednisone treatment, Tocilizumab treatment, Methotrexate treatment - Giant Cell Arteritis | Phase 3 | Completed | Centre Hospitalier Universitaire Dijon | 230 | 2020-01-27 | 2026-10-30 |
| Drug-eluting Balloon for Treatment of Non-atherosclerotic Renal Artery Stenosis Angioplasty with paclitaxel eluting balloon, Angioplasty with plain old balloon - Hypertension, Renovascular | Phase 3 | Unknown | Peking Union Medical College Hospital | 90 | 2019-10-01 | 2020-04-29 |
| A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis Upadacitinib, Corticosteroid (CS), Placebo - Giant Cell Arteritis (GCA) | Phase 3 | Completed | AbbVie | 429 | 2019-01-24 | 2026-02-24 |
| Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA Sarilumab SAR153191, Sarilumab matching placebo, Prednisone - Giant Cell Arteritis | Phase 3 | Terminated | Sanofi | 83 | 2018-11-20 | 2022-03-28 |
| Anti-inflammatory Treatment for Inactive Takayasu Arteritis Prednisone, cyclophosphamide - Takayasu Arteritis, Anti-Inflammatory Agents | Phase 2 / Phase 3 | Unknown | Chinese Academy of Medical Sciences, Fuwai Hospital | 40 | 2018-06-01 | 2018-06-08 |
| An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Tocilizumab - Giant Cell Arteritis | Phase 3 | Completed | Hoffmann-La Roche | 3 | 2017-10-25 | 2020-09-04 |
| A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) Abatacept, Placebo, Glucocorticoid Treatment - Giant Cell Arteritis | Phase 3 | Withdrawn | Bristol-Myers Squibb | 2017-07-15 | 2017-07-12 |
Showing 20 of 29. Sign in to see all of them.
Giant Cell Arteritis (20) · Takayasu Arteritis (7) · Vasculitis (4) · Polymyalgia Rheumatica (2) · Vascular Diseases (2) · Acquired Immunodeficiency Syndrome (1) · Acute Coronary Syndrome (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Blindness (1) · Cardiovascular Diseases (1) · Cerebrovascular Disorders (1) · Churg-Strauss Syndrome (1) · Fibromuscular Dysplasia (1)
Cardiovascular Diseases (28) · Skin Diseases (28) · Skin Diseases, Vascular (28) · Skin and Connective Tissue Diseases (28) · Vascular Diseases (27) · Vasculitis (25) · Brain Diseases (21) · Central Nervous System Diseases (21) · Immune System Diseases (21) · Nervous System Diseases (21) · Autoimmune Diseases (20) · Autoimmune Diseases of the Nervous System (20) · Cerebrovascular Disorders (20) · Vasculitis, Central Nervous System (20)
Prednisone (5) · Adrenal Cortex Hormones (4) · tocilizumab (4) · Abatacept (2) · Blood Specimen Collection (2) · Prednisolone (2) · Surveys and Questionnaires (2) · secukinumab (2) · upadacitinib (2) · Adalimumab (1) · Angioplasty (1) · Azathioprine (1) · Cyclophosphamide (1) · Eplerenone (1) · Glucocorticoids (1)
Assistance Publique - Hôpitaux de Paris (4) · AbbVie (2) · Centre Hospitalier Universitaire Dijon (2) · Chinese SLE Treatment And Research Group (2) · Hoffmann-La Roche (2) · Novartis Pharmaceuticals (2) · University Hospital, Caen (2) · Bristol-Myers Squibb (1) · Centre Hospitalier Universitaire de Nice (1) · Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal (1) · Chinese Academy of Medical Sciences, Fuwai Hospital (1) · GlaxoSmithKline (1) · Insel Gruppe AG, University Hospital Bern (1) · Janssen Pharmaceutical K.K. (1) · Massachusetts General Hospital (1)
France (17) · Germany (8) · United States (8) · Canada (7) · Belgium (6) · Italy (6) · Netherlands (6) · Spain (6) · United Kingdom (6) · Australia (5) · Denmark (5) · Sweden (5) · Switzerland (5) · China (4) · Hungary (4)
Xinping Tian, MD (2) · Carol A Langford, MD, MHS (1) · Jean-Paul Makhzoum, MD (1) · Jeffrey P Krischer, PhD (1)
PMID 10068416, PMID 16221103, PMID 16914703, PMID 17332971, PMID 17407214, PMID 17557758, PMID 20054700, PMID 23528439, PMID 23897775, PMID 27924855, PMID 28678392, PMID 28745999, PMID 30786937, PMID 30835950, PMID 31056661, PMID 32844378, PMID 32943098, PMID 34049857, PMID 34718434, PMID 36963127, PMID 37840134, PMID 38279390, PMID 38840219, PMID 39400109, PMID 40104212, PMID 40174237, PMID 40483523, PMID 41067765, PMID 42234457
2016 (2), 2017 (2), 2015 (1), 2018 (1), 2023 (1)